Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Metesa Medical ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   7.0% 17.6% 17.4% 20.2% 13.9% 20.3% 17.8% 17.8%   Credit score (0-100)   36 10 9 5 15 4 8 8   Credit rating   BBB B BB B BB B B B   Credit limit (kDKK)   0.0 -0.0 -0.0 -0.0 0.0 -0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   467 -298 -66.9 -107 584 -176 0.0 0.0   EBITDA   467 -306 -86.0 -144 553 -177 0.0 0.0   EBIT   467 -306 -86.0 -144 553 -268 0.0 0.0   Pre-tax profit (PTP)   461.8 -312.3 -90.5 -145.2 550.8 -272.4 0.0 0.0   Net earnings   360.2 -312.3 -90.5 -145.2 429.6 -212.7 0.0 0.0   Pre-tax profit without non-rec. items   462 -312 -90.5 -145 551 -272 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   396 83.4 -7.0 -152 277 64.7 14.7 14.7   Interest-bearing liabilities   23.9 1.1 41.0 128 9.6 9.6 0.0 0.0   Balance sheet total (assets)   701 119 57.3 98.7 1,206 140 14.7 14.7   Net Debt   -456 -37.3 40.7 97.2 -952 -61.7 -14.7 -14.7     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   467 -298 -66.9 -107 584 -176 0.0 0.0   Gross profit growth   0.0% 0.0% 77.6% -59.7% 0.0% 0.0% 0.0% 0.0%   Employees   0 1 0 1 1 1 0 0   Employee growth %   0.0% 0.0% -100.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   701 119 57 99 1,206 140 15 15   Balance sheet change%   62.7% -83.0% -52.0% 72.2% 1,122.1% -88.4% -89.5% 0.0%   Added value   467.0 -306.0 -86.0 -144.1 553.3 -176.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 -91 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 -1.0 -2.0 -3.0 1.0 -1.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 102.5% 128.5% 134.8% 94.8% 152.2% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   82.9% -74.5% -93.5% -91.4% 75.9% -39.9% 0.0% 0.0%   ROI %   179.8% -121.4% -136.8% -170.0% 266.3% -148.5% 0.0% 0.0%   ROE %   167.0% -130.4% -128.5% -186.0% 228.4% -124.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   56.4% 69.9% -10.9% -60.7% 23.0% 46.3% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -97.6% 12.2% -47.3% -67.5% -172.2% 34.9% 0.0% 0.0%   Gearing %   6.0% 1.3% -582.4% -84.4% 3.5% 14.9% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   16.5% 51.0% 21.8% 1.3% 3.6% 43.3% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   2.3 3.3 0.9 0.4 1.3 1.9 0.0 0.0   Current Ratio   2.3 3.3 0.9 0.4 1.3 1.9 0.0 0.0   Cash and cash equivalent   479.6 38.4 0.3 31.3 962.1 71.3 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   395.8 83.4 -7.0 -152.2 277.4 64.7 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 -306 0 -144 553 -177 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 -306 0 -144 553 -177 0 0   EBIT / employee   0 -306 0 -144 553 -268 0 0   Net earnings / employee   0 -312 0 -145 430 -213 0 0